Cellectar Biosciences Approves Reverse Stock Split Proposal

Cellectar Biosciences ( (CLRB) ) has issued an update.

Cellectar Biosciences, Inc. held its 2025 Annual Meeting of Stockholders on June 13, 2025, where several key proposals were presented and voted upon. James V. Caruso and Frederick W. Driscoll were elected as Class II directors for three-year terms. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2025 was ratified. Stockholders approved a reverse stock split proposal allowing a split ratio between 1:10 and 1:30. Executive compensation was also approved on a non-binding advisory basis. The proposal to adjourn the meeting was not presented as it was rendered moot by the approval of the reverse stock split.

The most recent analyst rating on (CLRB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectar Biosciences stock, see the CLRB Stock Forecast page.

Spark’s Take on CLRB Stock

According to Spark, TipRanks’ AI Analyst, CLRB is a Underperform.

Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company’s valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.

To see Spark’s full report on CLRB stock, click here.

More about Cellectar Biosciences

Average Trading Volume: 11,934,237

Technical Sentiment Signal: Sell

Current Market Cap: $19.67M

Learn more about CLRB stock on TipRanks’ Stock Analysis page.